We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Rapid Test Identifies Bacteria from Blood Culture

By LabMedica International staff writers
Posted on 01 Feb 2011
A molecular based diagnostic test is now available that will identify three different Gram-negative bacteria in less than 90 minutes from positive blood cultures. More...


The assay uses peptide nucleic acid (PNA) probes to target species-specific ribosomal ribonucleic acid (rRNA) in live bacteria and yeast coupled with highly sensitive and specific fluorescence in situ hybridization (FISH).

The GNR Traffic Light PNA FISH test is capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa directly from positive blood cultures containing Gram-negative rods. The unique properties of the noncharged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn facilitates the development of very simple, yet very accurate tests that do not require the extensive sample preparation necessary for other nucleic acid technologies.

The assay is manufactured by AdvanDX, (Woburn, MA, USA) and has received 510(k) clearance from the US Food and Drug Administration (FDA; Silver Spring, MD, USA). The test is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results that enable clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections (BSI).

The GNR Traffic Light PNA FISH assay will enable microbiology laboratories to identify and report E. coli, K. pneumoniae, and P. aeruginosa from positive blood cultures 24-48 hours earlier than traditional methods. The rapid results will provide clinicians a "head start" on selecting appropriate and effective therapy for patients with Gram-negative bloodstream infections, which studies show may improve clinical outcomes, reduce incidence of adverse events and shorten hospital length of stay.

Related Links:
AdvanDX
FDA


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Kissing bugs can carry the parasite that causes Chagas disease (Photo courtesy of 123RF)

First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness

An estimated 6 to 8 million individuals across the globe are infected with Trypanosoma cruzi, the parasite responsible for Chagas disease, which claims over 10,000 lives annually. This disease doesn’t... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The new tool shines a light on elusive genomic patterns (Photo courtesy of Adobe Stock)

Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance

Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.